Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr1.40 SEK
Change Today 0.00 / 0.00%
Volume 3.3M
KARO On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
Stockholm
Frankfurt
As of 5:51 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

karo bio ab (KARO) Snapshot

Open
kr1.40
Previous Close
kr1.40
Day High
kr1.43
Day Low
kr1.35
52 Week High
03/19/15 - kr1.77
52 Week Low
12/17/14 - kr0.51
Market Cap
1.3B
Average Volume 10 Days
5.0M
EPS TTM
kr-0.07
Shares Outstanding
689.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KARO BIO AB (KARO)

Related News

No related news articles were found.

karo bio ab (KARO) Related Businessweek News

No Related Businessweek News Found

karo bio ab (KARO) Details

Karo Bio AB (publ), a pharmaceutical company, focuses on the research and development of drugs for unmet medical needs primarily in Sweden. The company is involved in the preclinical development of drugs primarily in the fields of neuropsychiatry, inflammation, autoimmune diseases, and cancer. Its pipeline products include nuclear receptor that regulates various functions in the body affecting a range of diseases, such as inflammation, diabetes, dyslipidemia and osteoporosis, obesity, and certain forms of cancer; estrogen receptor beta for use in the areas of women’s health, depression, and certain forms of cancer; and RORgamma for the treatment of autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, psoriasis, and multiple sclerosis. The company has collaboration agreements with Pfizer Inc. to discover and develop compounds for the treatment of autoimmune diseases; and 4D Science GmbH to develop treatments for fibrotic diseases. Karo Bio AB (publ) was founded in 1987 and is headquartered in Huddinge, Sweden.

24 Employees
Last Reported Date: 04/8/15
Founded in 1987

karo bio ab (KARO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

karo bio ab (KARO) Key Developments

Karo Bio AB Announces Earnings Results for the First Quarter Ended March 31, 2015

Karo Bio AB announced earnings results for the first quarter ended March 31, 2015. The company reported that net loss attributable to shareholders in the parent company for the first quarter ended March 31, 2015 was SEK 15.34 million, or SEK 0.02 loss per share, compared to a net loss attributable to shareholders in the parent company of SEK 13.38 million, or SEK 0.02 loss per share, for the same quarter ended March 31, 2014. Net sales for the first quarter ended March 31, 2015 were SEK 425,000, compared to SEK 6.36 million for the same quarter ended March 31, 2014. Operating loss for the first quarter ended March 31, 2015 was SEK 15.35 million, compared to an operating loss of SEK 13.4 million for the same quarter ended March 31, 2014.

Karo Bio Aktiebolag (publ), Special/Extraordinary Shareholders Meeting, May 25, 2015

Karo Bio Aktiebolag (publ), Special/Extraordinary Shareholders Meeting, May 25, 2015., at 15:00 Central European Standard Time. Location: Hörsalen, Novum Science Park. Agenda: To approve the Board's resolution on a new share issue (rights issue); and to approve the resolution on the authorization of the Board to resolve on a new share issue at over-subscription (over-allotment option).

Karo Bio Announces Unaudited Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

Karo Bio Aktiebolag (publ) reported unaudited consolidated and parent earnings results for the first quarter ended March 31, 2015. For the period, on consolidated basis the company reported an operating loss of SEK 15,345,000 compared to SEK 13,378,000 a year ago. Cash flow used in operating activities was SEK 19,388,000 compared to SEK 13,137,000 a year ago. Investments in equipment was SEK 20,000 compared to SEK 1,067,000 a year ago. On parent basis, for the company reported net loss of SEK 15,344,000 on net sales of SEK 425,000 compared to loss of SEK 13,375,000 on net sales of SEK 6,360,000 a year ago. Operating loss was SEK 15,353,000 compared to loss of SEK 13,398,000 a year ago. The decrease in net sales is mainly explained by the ending of the research funding from Pfizer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KARO:SS kr1.40 SEK 0.00

KARO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KARO.
View Industry Companies
 

Industry Analysis

KARO

Industry Average

Valuation KARO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.3x
Price/Book 39.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 56.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KARO BIO AB, please visit www.karobio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.